Article Text

Download PDFPDF

468 Racial disparities in patients with covid-19 infection and gynecologic malignancy
  1. Olivia Lara1,
  2. Maria Smith2,
  3. Yuyan Wang3,
  4. Roisin O’cearbhaill4,
  5. Stephanie Blank5,
  6. Anne Knisely6,
  7. Jennifer Mceachron7,
  8. Lisa Gabor8,
  9. Eloise Chapman-Davis9,
  10. Justin Jee4,
  11. Sara Isani8,
  12. Mengling Liu3,
  13. Jason Wright6 and
  14. Bhavana Pothuri1
  1. 1Nyu Langone Health; Obstetrics and Gynecology
  2. 2NYU Langone Health, New York, United States
  3. 3Nyu Langone Health; Population Health
  4. 4Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College; Medical Oncology
  5. 5Icahn School of Medicine at Mount Sinai; Obstetrics, Gynecologic and Reproductive Science
  6. 6College of Physicians and Surgeons, Columbia University; Obstetrics and Gynecology
  7. 7State University of New York Downstate Medical Center; Obstetrics and Gynecology
  8. 8Montefiore Medical Center and Albert Einstein College of Medicine; Obstetrics and Gynecology and Women’s Health
  9. 9Cornell University; Obstetrics and Gynecology


Introduction/Background Mounting evidence suggests disproportionate COVID-19 hospitalizations and deaths due to racial disparities. The association of race in a cohort of gynecologic oncology patients with SARS-CoV-2 infection is unknown.

Methodology Data were abstracted from gynecologic oncology patients with COVID-19 infection among 8 New York City (NYC) area hospital systems. Multivariable mixed-effects logistic regression model accounting for county clustering was utilized to analyse COVID-19 related hospitalization and mortality.

Results Of 193 patients with gynecologic cancer and COVID-19, 67 (34.7%) were Black and 126 (65.3%) were non-Black. Black patients were more likely to require hospitalization compared with non-Black patients (71.6% [48/67] vs. 46.0% [58/126], P=.001). Of 34 (17.6%) patients who died from COVID-19, 14 (41.2%) were Black. Among those hospitalized, Black patients compared to non-Black patients were more likely to: have ≥ 3 comorbidities (81.1% [30/37] vs 59.2% [29/49], P=.05); reside in Brooklyn (81.0% [17/21] vs 44.4% [12/27], P=.02); live with family (69.4% [25/36] vs 41.6% [37/89], P=.009); and have public insurance (79.6% [39/49] vs 53.4% [39/73], P=.006). In multivariable analysis, for patients younger than 65 years of age, Black patients were more likely to require hospitalization compared to non-Black patients (OR, 4.87; 95% CI 1.82 to 12.99, P=.002).

Conclusion Although Black patients with gynecologic cancer represented only 1/3 of patients, they accounted for disproportionate rates of hospitalization (>45%) and death (>40%) due to COVID-19 infection; younger Black patients had nearly 5-fold greater risk of hospitalization. Efforts to understand and improve these disparities in COVID-19 outcomes in Black patients are critical.

Disclosures B.P. reports grants, personal fees and non-financial support outside the submitted work; institutional PI for industry sponsored trials from Tesaro/GSK, AstraZeneca, Merck, Genentech/Roche, and Clovis Oncology. Compensated advisory boards include Tesaro/GSK, AstraZeneca, Merck and Eisai. J.J. reports a patent license from MDSeq Inc. R.OC reports personal fees from Tesaro, GlaxoSmithKline, Regeneron and Genentech USA, outside the submitted work and non-compensated steering committee member for the PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies. R.OC’s institute receives funding for clinical research from Celgene/Juno, Tesaro/GSK, Ludwig Cancer Institute, Abbvie, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, Marker Therapeutics, Syndax Pharmaceuticals, Genmab Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, Gynecologic Oncology Foundation. S.V.B. has research collaborations with Roche/Genentech, Tesaro/GK, Seattle Genetics, Merck and Asta Zeneca

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.